Pediatric Hematology/Oncology
Clinical discussions on pediatric blood disorders, childhood cancers, and specialized treatment protocols.
Recent Discussions
For a young male with Stage III intermediate risk NSGCT with active 1 ppd smoking history but normal PFTs and DLCO results, would you still consider use of BEP x 4?
I agree with Dr. @Dr. First Last. However, intermediate risk is between good risk and advanced disease, and in my opinion, despite the NCCN guidelines, I have never seen the logic nor the necessity of treating ALL intermediate patients the same as advanced disease with BEP X 4. Most of my intermedia...
Are there best practices or data regarding the use of open notes among oncology patients?
The 21st Century Cures Act regulation (effective April 2021) required that clinical notes such as consult and office notes be shared with patients, e.g. “open notes.” In general, surveys of patients with cancer and their clinicians suggest that open notes are viewed favorably (Salmi et al., PMID 330...
Do you treat stage 1 non-seminoma differently if there is a component of embryonal carcinoma?
No.
What are your recommendations for a male patient who was recently started on imatinib and wants to conceive?
Great question. This comes up often. For males, they can continue to take their CML TKI and conceive a child. Of course, this is much more complicated for women as they should not be pregnant while taking a TKI. I would say that if the patient is having difficulties conceiving, he should undergo a ...
Would you consider using DOACs in a young patient with SLE and Libman-Sacks endocarditis, who is negative for APS?
In this scenario, our patient with lupus is young and does not have features of APS. Nevertheless, any patient with Libman Sacks endocarditis carries a heightened risk for embolization. Regarding anticoagulation, the literature on this subject is anecdotal and conflicting with some authors recommend...
In a patient with stage 1 mixed germ cell tumor who cleared tumor markers post-orchiectomy but with subsequent rise to borderline abnormal within 6 weeks, would you treat with 3 cycles BEP as for S1 disease?
Several points to begin with. My strong preference is to recommend active surveillance for all well documented clinical stage 1 nonseminoma whether or not there is embryonal predominance or lymphovascular invasion present. Second, I do not make treatment decisions based on borderline abnormal normal...
How do you manage patients with chemotherapy-induced paronychia?
I manage patients with chemotherapy-induced paronychia with a few tricks: First, ensure that there is no infection (active drainage, especially purulent) is more indicative of infection, as well as appropriate hygiene. Topical steroids and soothing soaks (such as Domeboro or diluted distilled white ...
Do you routinely offer antiviral prophylaxis for patients receiving chemoimmunotherapy?
Yes, with R-CHOP and similar therapies for anyone who may have had chickenpox. I have seen shingles during treatment. I have not been doing routinely for younger patients who had VZV vaccines. Yes also for anyone with a history of HSV. Usually acyclovir BID.
Would you anticoagulate recurrent venous thromboembolism in a patient with Ehlers Danlos syndrome?
Yes, but know the hx of bleeding. Would use low dose Coumadin one 1.5 to 2, have good antidotes for Coumadin.
Based on recent data would you consider adding ATRA to low dose rituximab for steroid refractory ITP?
This is hard to answer in the absence of much more information about the patient. In a steroid refractory patient, it is important to understand why. This puts the patient immediately into a meeting refractory group (not responding to steroids). If there is an immediate need, IVIG is better. If the ...